Completion of Share Purchase Plan

Microba Life Sciences Limited (ASX: MAP) (**Microba** or the **Company**) is pleased to advise that it has completed its capital raising, comprising the institutional Placement announced on 12 June 2026 and the Share Purchase Plan (SPP), which closed at 5:00pm AEST on 22 July 2026. Together, the Placement and SPP have raised approximately $5.41 million before costs.

Key Highlights

- Microba has completed its capital raising, with the institutional Placement and Share Purchase Plan (SPP) together raising approximately $5.41 million before costs
- The $5.0 million institutional Placement announced on 12 June 2026 was complemented by the SPP, which gave eligible shareholders the opportunity to invest at the same price as institutional investors, with no brokerage or fees
- The SPP raised $407,500 through the issue of 8,150,000 New Shares at $0.05 per New Share, with every valid application satisfied in full and no scale back applied.
- Eligible SPP shareholders will receive one free attaching New Option for every New Share, with 8,150,000 New Options to be issued, exercisable at $0.0625 and expiring three years from the date of issue
- Funds will support the continued growth of Microba's core diagnostics business across Australia and the UK, the delivery of a new testing product, and working capital

Microba Chief Executive Officer, Luke Reid, said: "I would like to thank our shareholders for their continued support of Microba. Completing this capital raising gives us the financial strength to keep expanding clinical adoption of our microbiome testing across Australia and the UK, and to bring our new testing product to market. We are grateful to have shareholders who share our conviction in the opportunity ahead."

SPP Overview

The SPP gave eligible shareholders in Australia and New Zealand the opportunity to invest on the same terms as institutional investors in the Placement. The SPP raised $407,500 through the issue of 8,150,000 New Shares at $0.05 per New Share. Every valid application will be satisfied in full, with no scale back applied. New Shares issued under the SPP will rank equally with existing Microba ordinary shares from their date of issue. Eligible shareholders will also receive one free attaching New Option for every New Share, exercisable at $0.0625 each on or before the date three years after their issue.

The SPP was conducted under the prospectus dated 19 June 2026 issued under section 713 of the Corporations Act 2001 (Cth).

The proceeds strengthen Microba's balance sheet and will support the continued expansion of clinical adoption of the Company's microbiome testing across its Australian and UK operations.

General meeting and Placement

The issue of securities under the SPP, and the issue of the second tranche of the institutional Placement (Tranche 2 Placement), were subject to shareholder approval. Microba held its general meeting on 24 July 2026, at which all resolutions were passed.

Following that approval, Microba will issue on 29 July 2026:

- 8,659,785 New Shares under the Tranche 2 Placement;
- 100,004,240 New Options under the Placement, being one New Option for every Placement New Share across both tranches; and
- 8,150,000 New Shares and 8,150,000 New Options under the SPP.

The first tranche of the Placement, comprising 91,344,455 New Shares, settled on 17 June 2026. All New Options are exercisable at $0.0625 each on or before the date three years after their issue.

Issue and trading timetable

- New Shares and New Options under the SPP and Placement are expected to be issued on Wednesday, 29 July 2026
- Trading of New Shares issued under the SPP is expected to commence on Thursday, 30 July 2026
- Holding statements are expected to be despatched on Friday, 31 July 2026

These dates are indicative only and may change at the Company's discretion, subject to the ASX Listing Rules and the Corporations Act 2001 (Cth).

This announcement has been authorised for release by the Chair and CEO.

For further information, please contact:

Dr Luke Reid
Chief Executive Officer
luke.reid@microba.com

Investor / Media Relations
investor@microba.com
https://ir.microba.com/welcome

About Microba Life Sciences Limited
Microba is at the forefront of microbiome health and human care. With world-leading science, insights and collaboration tools, Microba's vision is to deliver clinical-grade microbiome tests that help people live healthier, happier lives. Better science. Better insights. Better health. Microba - Expect better. www.microba.com